Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Zanubrutinib
Synonyms
Therapy Description

Zanubrutinib (BGB-3111) inhibits Bruton Tyrosine Kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing B-cells (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Zanubrutinib Brukinsa BGB-3111 BTK inhibitor 22 Brukinsa (zanubrutinib) inhibits Bruton tyrosine kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing cells (PMID: 31378456). Brukinsa (zanubrutinib) is FDA approved for use in patients with mantle cell lymphoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown mantle cell lymphoma not applicable Zanubrutinib FDA approved Actionable In a Phase II trial (BGB-3111-206) that supported FDA approval, Brukinsa (zanubrutinib) treatment resulted in an overall response rate of 83.5% (71/85, 50 complete response, 21 partial response) of patients with relapsed or refractory mantle cell lymphoma who received 1 to 4 prior treatments (Blood (2018) 132 (Supplement 1): 148; NCT03206970). detail... detail...
Unknown unknown mantle cell lymphoma not applicable Zanubrutinib Preclinical - Cell line xenograft Actionable In a preclinical study, Brukinsa (zanubrutinib) inhibited BTK signaling and proliferation of mantle cell lymphoma cell lines in culture, and demonstrated antitumor activity in a mantle cell lymphoma cell line xenograft model (ibrutinib) (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2597). detail...
Unknown unknown CLL/SLL not applicable Zanubrutinib Phase I Actionable In a Phase I trial, Brukinsa (zanubrutinib) treatment resulted in an overall response rate of 96.2% (75/78, 2 complete response, 63 partial response (PR), 10 PR with lymphocytosis) in patients with CLL/SLL (PMID: 31340982; NCT02343120). 31340982
Unknown unknown diffuse large B-cell lymphoma not applicable Zanubrutinib Preclinical - Cell line xenograft Actionable In a preclinical study, Brukinsa (zanubrutinib) inhibited BTK signaling and proliferation of diffuse large B-cell lymphoma (DLBCL) cell lines in culture, and demonstrated antitumor activity in a DLBCL cell line xenograft model, with improved efficacy compared to Imbruvica (ibrutinib) (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2597). detail...

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02343120 Phase I Zanubrutinib Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Active, not recruiting
NCT03846427 Phase II Zanubrutinib Study of Zanubrutinib (BGB-3111) in Patients With Marginal Zone Lymphoma Active, not recruiting
NCT03734016 Phase III Ibrutinib Zanubrutinib A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting
NCT03336333 Phase III Zanubrutinib Bendamustine + Rituximab A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL Recruiting
NCT04052854 Expanded access Zanubrutinib A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies Available
NCT04170283 Phase III Zanubrutinib Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies Enrolling by invitation
NCT04116437 Phase II Zanubrutinib A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib Recruiting
NCT03053440 Phase III Ibrutinib Zanubrutinib A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting


Additional content available in CKB BOOST